Emerson Resources Expands Pharmaceutical Development and Analytical Capabilities

Company Adds Pilot Scale, Closed Loop Spray Drying Technologies and Solid-State Characterization Laboratory to Facility

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Emerson Resources

Drug solubility enhancement will be the key to unlocking the potential of many future therapies. Our investment in these new capabilities underscores our commitment to quickly and efficiently driving the development of these therapies.

Norristown, Pennsylvania (PRWEB) August 13, 2014

Emerson Resources, Inc., a premier pharmaceutical development company, today announced the expansion of its formulation development, clinical supplies manufacturing, and analytical capabilities. The Company now offers feasibility and pilot scale spray drying for drug solubility enhancement, as well as a more robust analytical offering, via the addition of a new solid-state characterization laboratory. This growth reflects the Company’s focus on delivering pragmatic yet creative solutions to its clients, through the use of cutting-edge technologies and application of innovative problem solving.

The Company’s robust suite of pharmaceutical manufacturing equipment now features two Spray Dryers, the Buchi B290 Spray Dryer and the GEA Mobile Minor, both of which are closed-loop for organic solvents. The Mobile Minor is equipped with two-fluid and pressure nozzle spray systems to accommodate a wide range of applications.

As well as expanding its manufacturing capabilities, Emerson Resources has added a solid-state characterization laboratory to its 46,000 square foot facility, which will enable Emerson to better meet the analytical needs of its clients. The new laboratory includes a wide range of technologies such as TA Instruments Q2000 Modulated Differential Scanning Calorimeter (mDSC), JEOL Neoscope JCM-6000 Scanning Electron Microscope (SEM), Rigaku MiniFlex 600 X-Ray Diffractometer (XRD) and the Malvern Mastersizer 3000 Particle Size Analyzer (PSA).

“Drug solubility enhancement will be the key to unlocking the potential of many future therapies. Our investment in these new capabilities underscores our commitment to quickly and efficiently driving the development of these therapies,” said Rob Tuohy, Sr. Vice President & Chief Scientific Officer. “Our recent expansion, combined with our established track record of creativity, flexibility, and quality, will undoubtedly support the measurable success of our clients.”

                                                             ####

About Emerson Resources
For more than 12 years, Emerson Resources, a premier pharmaceutical development company, has delivered value-added service, ingredients and expertise to clients in the pharmaceutical and biotech industries. Emerson Resources is a leader in dosage form development, manufacturing cGMP clinical supplies, analytical method development, analytical method validation, release testing and stability testing. Based in Norristown, Pennsylvania, the Company’s expansive facility features development and analytical laboratories, a cGMP clinical supplies manufacturing plant, and a specialty ingredients excipients manufacturing center. For more information, visit http://www.emersonresources.com.


Contact